Spike Glycoprotein, Coronavirus
"Spike Glycoprotein, Coronavirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion.
| Descriptor ID |
D064370
|
| MeSH Number(s) |
D12.776.543.512.500.665 D12.776.964.970.880.910.665
|
| Concept/Terms |
Spike Glycoprotein, Coronavirus- Spike Glycoprotein, Coronavirus
- Coronavirus Spike Glycoprotein
- Spike Protein, Coronavirus
- Coronavirus Spike Protein
- Glycoprotein S, Coronavirus
- Spike Glycoproteins, Coronavirus
|
Below are MeSH descriptors whose meaning is more general than "Spike Glycoprotein, Coronavirus".
Below are MeSH descriptors whose meaning is more specific than "Spike Glycoprotein, Coronavirus".
This graph shows the total number of publications written about "Spike Glycoprotein, Coronavirus" by people in this website by year, and whether "Spike Glycoprotein, Coronavirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2021 | 1 | 5 | 6 |
| 2022 | 0 | 5 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Spike Glycoprotein, Coronavirus" by people in Profiles.
-
Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody. J Clin Invest. 2022 12 01; 132(23).
-
COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine. PLoS One. 2022; 17(9):e0273323.
-
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19. J Vis Exp. 2022 02 16; (180).
-
An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. Cell. 2022 02 17; 185(4):614-629.e21.
-
Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. Nat Commun. 2022 02 03; 13(1):688.
-
The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. Clin Sci (Lond). 2021 12 22; 135(24):2667-2689.
-
Next-Generation Serology by Mass Spectrometry: Readout of the SARS-CoV-2 Antibody Repertoire. J Proteome Res. 2022 01 07; 21(1):274-288.
-
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer. 2021 12; 2(12):1321-1337.
-
Eugenol, a Component of Holy Basil (Tulsi) and Common Spice Clove, Inhibits the Interaction Between SARS-CoV-2 Spike S1 and ACE2 to Induce Therapeutic Responses. J Neuroimmune Pharmacol. 2021 12; 16(4):743-755.
-
Selective Inhibition of the Interaction between SARS-CoV-2 Spike S1 and ACE2 by SPIDAR Peptide Induces Anti-Inflammatory Therapeutic Responses. J Immunol. 2021 11 15; 207(10):2521-2533.